Micoli Francesca, Nakakana Usman N, Berlanda Scorza Francesco
GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.
Vaccines (Basel). 2022 Feb 18;10(2):328. doi: 10.3390/vaccines10020328.
Shigellosis remains a major public health problem around the world; it is one of the leading causes of diarrhoeal disease in low- and middle-income countries, particularly in young children. The increasing reports of cases associated with anti-microbial resistance are an additional element of concern. Currently, there are no licensed vaccines widely available against , but several vaccine candidates are in development. It has been demonstrated that the incidence of disease decreases following a prior infection and that serum and mucosal antibody responses are predominantly directed against the serotype-specific O-antigen portion of lipopolysaccharide membrane molecules. Many vaccine candidates are indeed O-antigen-based. Here we present the journey towards the development of a potential low-cost four-component vaccine, eliciting broad protection against the most prevalent serotypes, that makes use of the GMMA (Generalized Modules for Membrane Antigens) technology, a novel platform based on bacterial outer membranes for delivery of the O-antigen to the immune system.
志贺氏菌病仍是全球主要的公共卫生问题；它是低收入和中等收入国家腹泻病的主要病因之一，在幼儿中尤为常见。与抗菌药物耐药性相关病例的报告日益增多，这是另一个令人担忧的因素。目前，尚无广泛可用的针对志贺氏菌的许可疫苗，但有几种候选疫苗正在研发中。已有研究表明，先前感染志贺氏菌后疾病发病率会降低，并且血清和黏膜抗体反应主要针对脂多糖膜分子的血清型特异性O抗原部分。许多志贺氏菌候选疫苗确实是以O抗原为基础的。在此，我们介绍一种潜在的低成本四组分志贺氏菌疫苗的研发历程，该疫苗可诱导针对最常见志贺氏菌血清型的广泛保护，它利用了GMMA（膜抗原通用模块）技术，这是一种基于细菌外膜的新型平台，用于将O抗原递送至免疫系统。
